CASI Pharmeceuticals

View All
Casi Pharmaceuticals

CASI Pharmaceuticals CEO Ken K. Ren, PhD rang the closing bell at NASDAQ on Thursday, June 11, 2015 4PM. Click the link below to access NASDAQ’s video archive to view the ceremony.

About Us

A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.

Learn More

In the News

CASI's turnaround turns eastward; firm seeks to be Celgene of China

Read Article →


Senescence as a Mechanism of Resistance to Aurora Kinase Inhibition with ENMD-2076 in p53 mutated Triple-Negative Breast Cancer (TNBC) Models

Download →


A Phase II Study of Oral ENMD-2076 in Advanced Soft Tissue Sarcomas

Download →

Receive press releases via email